Trending stocks today
Viatris (VTRS-Q)
NASDAQ:VTRS
13.13
0.08
(0.61%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Stocks climb ahead of U.S. MidtermsThis summary was created by AI, based on 7 opinions in the last 12 months.
Viatris, a pharma company trading at 5-8x earnings, has garnered mixed reviews from experts. While some see potential in the company's focus on new products, stock buybacks, and dividend yield, others are concerned about the lack of stock growth, risky acquisitions, and trigger of stop loss resulting in a net investment gain. Overall, the consensus is divided, and the stock is not well followed in the market.
$13.090
Owned
Great free cashflow, more than covers the 4% yield. Cheap PE at 4x earnings. Q2 results coming out in early August, where a couple of divestitures will be announced. Awaiting stock buyback. Paying down debt, making acquisitions. $12B market cap, but not well followed.
Stock's done nothing for him except pay a 4% dividend. A couple of more asset sales to go next quarter. He'd love it if they took the cash, paid down debt, and bought back shares. But management keeps making acquisitions, riskier. Trades at 3-4x earnings.
Our PAST TOP PICK with VTRS has triggered its stop at $11.50. To remain disciplined we recommend covering the position at this time. Along with previous recommendations, this will result in a net investment gain of 4%.
We reiterate VTRS, producer of Lipitor as one of its brands, as a TOP PICK. Management has simplified its product offering portfolio and committed to returning half of free cash cash flow to shareholders through aggressive share buybacks. It trades at 8x earnings and below book value. Cash reserves are growing as debt is aggressively retired. Its dividend is backed by a payout ratio under one-third of cash flow. We recommend trailing up the stop (from $8.50) to $10.50, looking to achieve $14 -- upside potential of 19%. Yield 4.0%
(Analysts’ price target is $14.13)The pharma company produces Lipitor as one of its brands. It has embarked on a divestiture strategy that is allowing it to focus on core competencies and reduce costs. The are on target for $450 million in new product launches. It trades at 7x earnings and below book value. Cash reserves are growing as debt is aggressively retired. Its dividend is backed by a payout ratio under one-third of cash flow. We recommend placing a stop-loss at $8.50, looking to achieve $41 -- upside potential of 30%. Yield 4.5%
(Analysts’ price target is $14.11)Share price flat, but owns shares.
Excellent business within healthcare sector.
Getting into new business lines.
4% dividend yield with lots of free cash flow.
Share buybacks good for shareholders.
Trading at 4x earnings.
Product of recent merger of two separate pharma business'.
New CEO - remains to be seen whether he will preform.
Would like to see stabilization on business before investing.
Too early to invest.
It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4 Hold 10 Sell 0
Global healthcare, mix of branded drugs and generics. Drug business has had a good run, but there's going to be significant pushback on the outsized profits, both globally and in the US. He prefers medical devices.
Viatris(VTRS-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 3
Neutral - Hold Signals / Votes : 2
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 5
Viatris(VTRS-Q) Frequently Asked Questions
What is Viatris stock symbol?
Viatris is a American stock, trading under the symbol VTRS-Q on the NASDAQ (VTRS). It is usually referred to as NASDAQ:VTRS or VTRS-Q
Is Viatris a buy or a sell?
In the last year, 5 stock analysts published opinions about VTRS-Q. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Viatris.
Is Viatris a good investment or a top pick?
Viatris was recommended as a Top Pick by on . Read the latest stock experts ratings for Viatris.
Why is Viatris stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Viatris worth watching?
5 stock analysts on Stockchase covered Viatris In the last year. It is a trending stock that is worth watching.
What is Viatris stock price?
On 2024-11-20, Viatris (VTRS-Q) stock closed at a price of $13.13.
It is a pharma company trading at 5X earnings. It is buying back stock, as much as 5% and has a slew of new products.